10.11.2021 • NewsAstraZenecaCovis pharma

AstraZeneca Sells COPD Drug Rights to Covis

AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease (COPD) to Switzerland’s Covis Pharma for $270 million. The transaction is expected to close in the fourth quarter of 2021.

The drugs are Eklira, known as Tudorza in the US, and Duaklir, both in dry powder form and delivered via the Genuair breath-actuated multi-dose inhaler. They generated undisclosed  revenue of $143 million last year in the countries covered by the agreement.

AstraZeneca licensed the global rights to both products from Almirall in 2014.

Covis Pharma previously acquired the rights to three other respiratory medicines from the Anglo-Swedish drugmaker in 2018. These were Alvesco, used to treat persistent asthma, and Omnaris and Zetonna for treating nasal symptoms associated with rhinitis. Covis paid AstraZeneca $350 million, in addition to conditional sales-related payments of up to $21 million over four years from 2019.

Author: Elaine Burridge, Freelance Journalist

AstraZeneca has agreed to transfer its global rights to two drugs for treating...
AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease to Covis Pharma for $270 million. The drugs are Eklira, known as Tudorza in the US, and Duaklir and the transfer is due to close in Q4 2021. (c) AstraZeneca

Company

Logo:

AstraZeneca

Byggrad 2/4
15185 Södertälje
Sweden

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.